86 related articles for article (PubMed ID: 38531950)
1. Reverse Phase Proteomic Array Profiling of Asparagine Synthetase Expression in Newly Diagnosed Acute Myeloid Leukemia.
Narayanan N; Marvin-Peek J; Abouelnaaj MK; Majid D; Wang B; Brown BD; Qiu Y; Kornblau SM; Abbas HA
J Proteome Res; 2024 Jun; ():. PubMed ID: 38829961
[TBL] [Abstract][Full Text] [Related]
2. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia.
Jonas BA; Pollyea DA
Leukemia; 2019 Dec; 33(12):2795-2804. PubMed ID: 31628431
[TBL] [Abstract][Full Text] [Related]
3. Proteomics for optimizing therapy in acute myeloid leukemia: venetoclax plus hypomethylating agents versus conventional chemotherapy.
de Camargo Magalhães ES; Hubner SE; Brown BD; Qiu Y; Kornblau SM
Leukemia; 2024 May; 38(5):1046-1056. PubMed ID: 38531950
[TBL] [Abstract][Full Text] [Related]
4. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
5. Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure.
Short NJ; Venugopal S; Qiao W; Kadia TM; Ravandi F; Macaron W; Dinardo CD; Daver N; Konopleva M; Borthakur G; Shpall EJ; Popat U; Champlin RE; Mehta R; Al-Atrash G; Oran B; Jabbour E; Garcia-Manero G; Issa GC; Montalban-Bravo G; Yilmaz M; Maiti A; Kantarjian H
J Hematol Oncol; 2022 Jan; 15(1):12. PubMed ID: 35093134
[TBL] [Abstract][Full Text] [Related]
6. A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.
Manda S; Anz BM; Benton C; Broun ER; Yimer HA; Renshaw JS; Geils G; Berdeja J; Cruz J; Melear JM; Fanning S; Fletcher L; Li Y; Duan Y; Werner ME; Potluri J; Pai MV; Donnellan WB
Hematol Oncol; 2024 May; 42(3):e3274. PubMed ID: 38711253
[TBL] [Abstract][Full Text] [Related]
7. Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia.
Othman TA; Azenkot T; Moskoff BN; Tenold ME; Jonas BA
Future Oncol; 2021 Aug; 17(23):2989-3005. PubMed ID: 34024158
[TBL] [Abstract][Full Text] [Related]
8. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study.
Mustafa Ali MK; Corley EM; Alharthy H; Kline KAF; Law JY; Lee ST; Niyongere S; Duong VH; Emadi A; Baer MR
Front Oncol; 2022; 12():858202. PubMed ID: 35433414
[TBL] [Abstract][Full Text] [Related]
10. Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets.
Griffen TL; Hoff FW; Qiu Y; Lillard JW; Ferrajoli A; Thompson P; Toro E; Ruiz K; Burger J; Wierda W; Kornblau SM
Blood Cancer J; 2022 Mar; 12(3):43. PubMed ID: 35301276
[TBL] [Abstract][Full Text] [Related]
11. Clinical relevance of proteomic profiling in
Hoff FW; Van Dijk AD; Qiu Y; Hu CW; Ries RE; Ligeralde A; Jenkins GN; Gerbing RB; Gamis AS; Aplenc R; Kolb EA; Alonzo TA; Meshinchi S; Qutub AA; De Bont ESJM; Horton TM; Kornblau SM
Haematologica; 2022 Oct; 107(10):2329-2343. PubMed ID: 35021602
[TBL] [Abstract][Full Text] [Related]
12. Ribosomal Protein S6: A Potential Therapeutic Target against Cancer?
Yi YW; You KS; Park JS; Lee SG; Seong YS
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008473
[TBL] [Abstract][Full Text] [Related]
13. A concise review on the molecular genetics of acute myeloid leukemia.
Padmakumar D; Chandraprabha VR; Gopinath P; Vimala Devi ART; Anitha GRJ; Sreelatha MM; Padmakumar A; Sreedharan H
Leuk Res; 2021 Dec; 111():106727. PubMed ID: 34700049
[TBL] [Abstract][Full Text] [Related]
14. RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences.
van Dijk AD; Griffen TL; Qiu YH; Hoff FW; Toro E; Ruiz K; Ruvolo PP; Lillard JW; de Bont ESJM; Burger JA; Wierda W; Kornblau SM
Leukemia; 2022 Mar; 36(3):712-722. PubMed ID: 34625713
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
